Global Hereditary Testing Market, By Hereditary Cancer Testing (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, Others), Hereditary Non-Cancer Testing (Genetic Tests, Newborn Genetic Screening, Preimplantation Genetic Diagnosis and Screening, Non-invasive Prenatal Testing (NIPT) and Carrier Screening Tests) – Industry Trends and Forecast to 2029.
Hereditary Testing Market Analysis and Size
The market for hereditary testing is predicted to expand significantly in the next years due to the rise in cancer and genetic illnesses, as well as increased knowledge and acceptance of personalised therapy. Pharmacogenomics, often known as drug-gene testing, has frequently used hereditary testing. Improvements in genetic testing methods are anticipated to accelerate market expansion.
Data Bridge Market Research analyses that the hereditary testing market which was USD 1.90 billion in 2021, would rocket up to USD 3.83 billion by 2029, and is expected to undergo a CAGR of 9.15% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hereditary Testing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Hereditary Cancer Testing (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, Others), Hereditary Non-Cancer Testing (Genetic Tests, Newborn Genetic Screening, Preimplantation Genetic Diagnosis and Screening, Non-invasive Prenatal Testing (NIPT) and Carrier Screening Tests)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
CENTOGENE N.V. (Germany), Ambry Genetics (U.S.), Myriad Genetics, Inc. (U.S.), NeoGenomics Laboratories (U.S.), Quest Diagnostics Incorporated (U.S.), PreventionGenetics (U.S.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Medical Diagnostic Laboratories, L.L.C. (U.S.), Natera (U.S.), Caris Life Sciences (U.S.), LabSolutions (U.S.), Progenity Inc. (U.S.), ARUP Laboratories (U.S.)
|
|
Market Opportunities
|
|
Market Definition
In hereditary testing, particular inherited variations (variants) in a person's genes are changed. On the probability of contracting diseases, genetic variations might have negative, positive, neutral (no effect), or ambiguous effects. There is evidence that certain genes with harmful mutations enhance the likelihood of acquiring cancer. It is estimated that 5 to 10% of all malignancies are caused by these hereditary variations.
Hereditary Testing Market Dynamics
Drivers
- Increasing prevalence of hereditary cancer
Cancer is a genetic disorder produced due to definite changes in genes that administrate cell efficacy, mainly moving their growth and duplication. Hereditary genetic mutations are the reason of ~5–10% of all cancers. The detectives have related mutations in precise genes with added 50 hereditary cancer syndromes which effects entities in emerging certain cancers.
- Development in genomic technology
Breast cancer is one of the most collective cancers in the world affecting almost 12.5% of women during their lifetime and 5%–10% of these patients have a hereditary form. BRCA1 and BRCA2 genes are the two most mutual mutated genes, but additional genes connected with hereditary breast cancer are emerging. New developments in genomic skills have directed to parallel testing of multiple genes.
Opportunities
Mutation in the genes is one factor that impacts the early detection of hereditary cancer, increasing market growth. At the same time, efficacy and cost-effectiveness over traditional testing methods also drive market growth. Moreover, mounting demand for initial discovery and precise analysis is a feature that drives market growth.
Restraints/Challenges
The performance of hereditary multigene panel testing raises several issues, such as the measures that the patients have to meet to undertake the test and the patient’s clinical association, which will obstruct the market growth.
This hereditary testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hereditary testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Hereditary Testing Market
Many of the industries across the world have been harmfully wedged over the last 18 months. This can be attributed to significant disturbances experienced by their respective industrialized and supply-chain processes as a result of various precautionary lockdowns and other restrictions governing establishments across the globe enforced. Furthermore, consumer demand has also subsequently reduced as persons are now more keen on eradicating non-essential expenses from their respective budgets. Most persons' general economic status has been severely affected by this outbreak. These aforementioned elements are predictable to burden the revenue trajectory of the global hereditary testing market over the forecast timeline.
Recent Development
- In June 2020, Invitae and ArcherDX announced Monday morning that the two genetic testing companies have agreed to syndicate in command to expand their footmark in the cancer genetics and precision oncology space.
Global Hereditary Testing Market Scope
The hereditary testing market is segmented on the basis of type, indication and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Multi Panel Test
- Single-site Genetic Test
Indication
- Breast Cancer
- Ovarian Cancer
- Colorectal Cancer
- Others
End-user
- Diagnostic Laboratory
- Hospitals
- Others
Hereditary Testing Market Regional Analysis/Insights
The hereditary testing market is analysed and market size insights and trends are provided by country, type, indication and end user as referenced above.
The countries covered in the hereditary testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America, the market is dominates the market owing to rising throwaway revenue, availability of advanced healthcare infrastructure, and increasing adoption of genetic testing in the region.
Asia-Pacific and Europe are expected to a significant growth rate in the coming years due to growing cancer cases and developing healthcare sectors.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The hereditary testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hereditary testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hereditary testing market. The data is available for historic period 2010-2020.
Competitive Landscape and Hereditary Testing Market Share Analysis
The hereditary testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hereditary testing market.
Some of the major players operating in the hereditary testing market are:
- CENTOGENE N.V. ( Germany)
- Ambry Genetics (U.S.)
- Myriad Genetics, Inc. (U.S.)
- NeoGenomics Laboratories (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- PreventionGenetics (U.S.)
- Fulgent Genetics (U.S.)
- Invitae Corporation (U.S.)
- Medical Diagnostic Laboratories, L.L.C. (U.S.)
- Natera (U.S.)
- Caris Life Sciences (U.S.)
- LabSolutions (U.S.)
- Progenity Inc. (U.S.)
- ARUP Laboratories (U.S.)
SKU-